Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/00051—Accessories for dressings
  • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
  • A01N59/16—Heavy metals; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/01—Non-adhesive bandages or dressings
  • A61F13/01008—Non-adhesive bandages or dressings characterised by the material
  • A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/722—Chitin, chitosan
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L15/28—Polysaccharides or their derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/906—Zingiberaceae (Ginger family)
  • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
  • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
  • A61L2300/104—Silver, e.g. silver sulfadiazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

• a multifunctional natural wound healing matrix A multifunctional natural wound healing matrix
• the present invention relates to the field of biotechnology/pharmaceutical/medical sciences.
• the present invention relates to the field of wound healing.
• the present invention relates to the field of wound healing matrix.
• the present invention provides a wound healing matrix which is made up of a variety of natural ingredients, all working in a synergistic way to achieve the desired results.
• Chitosan is a cationic polymer of natural origin and has been widely explored as a pharmaceutical excipient for a broad range of biomedical applications.
• Chitosan is linear polysaccharide composed of randomly distributed -(l-4)-linked D- glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is made by treating shrimp and other crustacean shells with the alkali sodium hydroxide. It is also being made from edible mushroom.
• Chitosan has a number of commercial and possible biomedical uses. It can be used in agriculture as a seed treatment and biopesticide, helping plants to fight off fungal infections.
• wine making it can be used as a fining agent, also helping to prevent spoilage.
• it can be used in a self-healing polyurethane paint coating.
• it may be useful in bandages to reduce bleeding and as an antibacterial agent; it can also be used to help deliver drugs through the skin.
• Chitosan has been found as being included as a soluble dietary fiber.
• a Zwitter-ion is a neutral molecule with a positive and a negative electrical charge at different locations within that molecule.
• Amino acids are the best-known examples of zwitterions. These compounds contain an ammonium and a carboxylate group, and can be viewed as arising via a kind of intra-molecular acid- base reaction.
• Silver nano-particles are silver particles of between 1 nm and 100 nm in size. Ionic silver has a long history of use in topical medical applications, and it has been shown that ionic silver, in the right quantities, is suitable in treating wounds. The US FDA has approved the use of a range of different silver-impregnated wound dressings. Silver nano-particles are now replacing silver sulfadiazine as an effective agent in the treatment of wounds.
• Lanolin is a yellowish waxy natural substance, having water repellent, antifungal and antibacterial properties. This is a useful skin protector because the oils in it are similar in composition to the oils secreted by human skin.
• the barrier formed on the skin by Lanoline allows penetration of moisture and air through it, which is very important for wound healing process. It also acts as a drug delivery system for transferring pharmaceutically active ingredients into the deeper layers of the skin.
• the invention provides an extracellular matrix for enhancing wound healing.
• the extracellular matrix comprises a recombinant fibronectin protein and a backbone matrix, wherein the recombinant fibronectin protein comprises peptides from two or more fibronectin domains.
• the extracellular matrix facilitates wound healing by providing homeostasis and, in addition, an environment that intrinsically recruits new tissue cells to the wound site.
• the extracellular matrix according to the subject invention is thus used in a method for enhancing wound healing. The method comprises applying the extracellular matrix to the wound.
• said adhesive composition further comprises at least one adhesive-enhancing agent whereby said agent is provided in a granular form, and preferably are a chitin and/or chitosan containing material.
• the present adhesive composition and matrix comprising such composition can be used as gluing composition, in particular in wound-healing and/or surgical applications.
• This invention relates to a preparation method and application of chitosan-based nano-fiber, in which the preparation method includes the following steps that the drugs or bio-activator such as growth factors are dissolved or dispersed in the chitisan adipic acid solution with the concentration of 0.01% to 3% (g/ml), and then the gelatin or collagen are added to dissolve.
• the biodegradable polyanion is dissolved in the de-ionized water and in preparation to be the solution with the same concentration as that of the chitisan.
• the mixed chitisan solution is slowly added into the poly-anion solution. After stirred uniformly, the nano-fiber loaded with the bio-activator is obtained through centrifuging, washing and cooling-drying.
• the chitosan-based nano-fiber prepared through the invention is biodegradable and has the imitated extracellular matrix structure, in which the controlled release of bio-activator can be achieved.
• the cellular compatibility of nano-fiber or the control of the release speed of the bio-activator can be improved. Therefore, the invention has a broad prospect in the fields of tissue engineer clinical wound healing and so on.
• Ganta s, Devalapally H,Amiji m. curcumin enhances oral bioavailability and antitumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation, j pharm sci 2010; 99: 4630-41.
• nanocurcumin a novel strategy for human cancer therapy, j nanobiotechnology 2007; 5: 3.
• This invention provides a method of use for a topical herbal formulation alone or in combination with oral administration of niacin (preferably a flush preparation) to prevent and/or treat dyshidrosis (pompholyx) and related skin diseases.
• niacin preferably a flush preparation
• the formulation may also be used to treat contact dermatitis, eczema, palmoplantar pustulosis and skin infections incurred by invasive pathogens such as mold, fungus and bacteria.
• the formulation is comprised of plant extracts and niacin, that when combined yield an effective multi-faceted pharmaceutical approach to treating dry skin disorders.
• the active ingredients within the formula include a combination of dry, aqueous, acid and alcohol extracts of black walnut hull (Juglans Nigra), wormwood ⁇ Artemisia Absinthium), tumeric rhizome ⁇ Curcuma Longa), garlic (Allium sativum), two or more herbal antibacterial agents from the group consisting of chamomile [Matricaria Chamomile), licorice root (Glycyrrhiza Glabra), St Johns wort [Hypericum perforatum), clove (Syzygium aromaticum), nutmeg (Myristica fragans), ginger (Zingiber officinale), frankincense (BosweHia carteri) and myrrh (Commiphora molmol), further combined with aloe vera and niacin.
• This invention relates to a hygroscopic pharmaceutical composition, which includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent.
• a foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected ⁇ from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
• the invention comprises several suitable antibiotics which also include microcrystalline and nano-crystalline particles of silver.
• the polymeric agents may include amine-bearing polymers such as chitosan and the like.
• the active agent is an antioxidant or a radical scavenger. Curcumin may be used as suitable antioxidant.
• This invention provides unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.
• Metallic Silver in small particles, including nanocrystalline silver, is used for antibacterial and wound healing purposes; other metal particles and mineral particles.
• Exemplary polymeric agents include amine- bearing polymers such as chitosan and the like.
• curcumin may be used as an anti-oxidant/radical scavenger.
• multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials.
• the multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix.
• a first functional group is nucleophilic
• a second functional group is electrophilic
• at least one additional functional group is nucleophilic or electrophilic.
• compositions and systems for forming cross linked biomaterials and associated methods of preparation and use are provided that readily crosslink in situ to provide cross linked biomaterials.
• the composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking.
• a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups.
• kits for delivery of the compositions are also provided as are kits for delivery of the compositions.
• Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
• crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked materials that may be used as adhesive compositions.
• the compositions comprise collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking.
• Methods for preparing and using the compositions are also provided.
• Exemplary uses include tissue augmentation, biologically active agent delivery, bioadhesion, prevention of adhesions following surgery or injury, and coating of surgically acceptable patches and solid implants, the latter including sutures.
• compositions and methods for removing urushiol and treating the resulting skin condition are directed to various compositions to treat the itching and conditions that result from contracting poison ivy, poison oak, and poison sumac, as well as other plant and substances that contain substances that lead to a skin reaction but that upon removal alleviate the symptoms of the condition.
• the compositions described herein are useful for removing urushiol after it has contacted the skin.
• compositions include granules or other scrubbing means to reach the urushiol in the skin, a mixture of surfactants to form a complex with the urushiol, counter-irritants to provide a soothing sensation to the irritated skin, and other functional ingredients to provide additional benefits to the individual who has contacted urushiol.
• a hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent.
• a foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
• the adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.
• the invention represents a method for making a resorbed polylactide matrix for cell culture and implantation for wound healing that involves preparing a resorbed hydrophilic porous polylactide matrix uniformly coated with type 1 microfibrillar collagen; for this purpose the hydrophilic porous polylactide matrix 13 mem to 15 mem thick with the pore diameter of 2 mem to 3 mem is prepared and then coated with 0.01% type 1 collagen in 0.1% acetic acid, incubated for 30 minutes at room temperature; thereafter, the matrix surface is washed in phosphate-buffered saline pH 7.4 to remove protein not bound with a substrate; the procedure of coating with the type 1 collagen solution is performed for two more times; the hydrophilic surface of the porous polylactide matrix uniformly coated with microfibrillar collagen structures of the diameter of 10 nm to 20 nm is applicable for human keratinocyte culture.
• the invention provides more effective structure.
• JP2011088927 (A) - MATRIX PROTEIN COMPOSITION FOR WOUND HEALING
• the present invention provides a pharmaceutical composition or cosmetic composition for healing wound, improving wound healing, regenerating or repairing soft tissue or preventing or treating inflammation by using an active enamel substance.
• an active enamel substance preparation for preparing the pharmaceutical composition or the cosmetic composition for wound healing, and the use of the preparation wherein the active enamel substance is an enamel matrix, an enamel matrix derivative and/or an enamel matrix protein.
• the invention provides a preparation method for a novel biomimetic matrix type biological wound healing material.
• small intestinal submucosa with a three-dimensional scaffold structure is compounded with platelet-rich blood plasma containing a specific proportion of bioactive factors, and a specific process is adopted to carry out modification to form the novel material containing biological induction factors, wherein the novel material has a three-dimensional biomimetic structure.
• the biomimetic matrix type biological wound healing material prepared by the method of the present invention the healing can be promoted, the physiological repair can be promoted, the pathological repair can be inhibited, and the regeneration repair efficiency and the repair quality of the damaged tissue can be improved.
• the novel biological wound healing material of the present invention can be used for repairs of various human soft tissues, membranous tissues or cavity walls, and for cavity filling, and can be used as the ideal extracellular matrix biomimetic material and the cell scaffold material for wound repairs of the tissues and the organs, promotion of wound healing, prevention of adhesion and the like.
• the invention refers to the field of medicine. It provides an antimicrobial and wound healing agent of hydrogel polymeric matrix used for wounds, burns and dermatologic disorders.
• the agent has the following formulation, wt %: polyvinylpyrrolidone - 2-10, agar - 1, polyethylene oxide - 1-3, an antimicrobial pharmaceutical substance selected from gentamycin and miramystine - 0.02-1, 0, water - the rest.
• the agent is prepared by cross-linking medical polymers under ionizing radiation.
• the hydrogel polymeric matrixes of the various area are sterile and ready for application on open wound surfaces.
• the agent exhibits elasticity, breaking strength, sorption properties in relation to wound exudate, transparency that enables following a course of wound process, painless removal from wound surface, creates an optimum microclimate in a wound (humidity, temperature).
• the present invention includes compositions and methods for the integration of non- allergenic nanocellulose into a wound bed.
• the composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, prosthesis, a fiber, a woven fiber, a bead, a strip, a clasp, catheter, a screw, a bone plate, a pin, a bandage or combinations thereof.
• the present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions such as wounds.
• the invention provides a wound healing composition comprising living cells such as fibroblasts within a support matrix such as fibrin, in which the cells have a wound healing phenotype, and in which the composition is single layered and has been incubated for up to about 8 days to allow development of the wound healing phenotype.
• the compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing.
• the invention provides a collagen gel and a preparation method thereof.
• the collagen gel comprises collagen and an antibacterial agent, wherein the antibacterial agent is at least one of chitosan and nano silver.
• the collagen gel also comprises a preservative, a. substrate, a dispersing agent, a film-forming agent and water; and lg of gel comprises 0.5 to 8.0mg of collagen, 0.001 to 15mg of antibacterial agent 1 to 50mg of preservative, 10 to 50mg of matrix, 50 to lOOmg of dispersing agent, 1 to lOmg of film-forming agent, and the balance of water.
• the method for preparing the collagen gel comprises the following steps of: performing dispersion and dissolution on the substrate by adopting the dispersing agent under ten-thousand grade clean environment; adding the dispersing agent, the substrate, the preservative, the antibacterial agent, and collagen solution into a vacuum emulsified homogenizer one by one; after fully mixing, standing and defoaming, filling the product.
• the collagen gel is applied to various open wounds and infected wounds, lightens hyperpigmentation, has good effect of accelerating wound healing, and can maintain long-term anti-bacteria function.
• the invention relates to a preparation method and application of chitosan-based nano-fiber, in which the preparation method includes the following steps that the drugs or bio-activator such as growth factors are dissolved or dispersed in the chitisan adipic acid solution with the concentration of 0.01% to 3% (g/ml), and then the gelatin or collagen are added to dissolve.
• the biodegradable polyanion is dissolved in the de-ionized water and in preaparation to be the solution with the same concentration as that of the chitisan.
• the mixed chitisan solution is slowly added into the polyanion solution. After stirred uniformly, the nano-fiber loaded with the bio-activator is obtained through centrifuging, washing and cooling-drying.
• the chitosan-based nano-fiber prepared through the invention is biodegradable and has the imitated extracellular matrix structure, in which the controlled release of bio-activator can be achieved.
• the cellular compatibility of nano-fiber or the control of the release speed of the bio-activator can be improved. Therefore, the invention has a broad prospect in the fields of tissue engineering, clinical wound healing and so on.
• the invention provides an antimicrobial composition comprising silver and at least one compound which interacts with a microbial cell wall to inhibit microbial silver resistance.
• the resistance inhibitors include molecules that can promote the transport of silver across the cell wall, and/or disrupt the cell wall to allow silver into the cell, and/or disrupt ion pump mechanisms in the cell wall for removing silver from the cell.
• Inhibitor compounds include fusaric acid, tocopherol, resveratrol, and myristic acid.
• wound dressings comprising the inventive compositions of the invention.
• the invention provides nanoparticles for delivery of drugs and/or nutraceuticals that include a fibroin polypeptide and a drug or nutraceutical, wherein the nanoparticle has a diameter of about 1 nm to about 500 nm, and compositions of the nanoparticles.
• the nanoparticles may further include a chitosan, or a proteoglycan such as decorin.
• methods of delivering a drug and/or nutraceutical to a subject that involves administering to the subject nanoparticles of the present invention.
• the nanoparticle for delivery of a drug and/or nutraceutical comprises:
• the nanoparticle has a diameter of about 1 nm to about 500 nm.
• the nanoparticle has a diameter of about 1 nm to about 300 nm.
• the invention provides nanoparticles for delivery of drugs and/or nutraceuticals that include a fibroin polypeptide and a drug or nutraceutical, wherein the nanoparticle has a diameter of about 1 nm to about 500 nm, and compositions of the nanoparticles.
• the nanoparticles may further include a chitosan, or a proteoglycan such as decorin.
• methods of delivering a drug and/or nutraceutical to a subject which involve administering to the subject nanoparticles of the present invention.
• Curcumin ⁇ Curcuma longa is a yellow compound having a molecular weight of 368.37 g/mol. This compound is an insoluble drug candidate which is conventionally limited to oral administration.
• the biological effects of curcumin include anti-tumor, anti-inflammatory and anti-oxidant activities.
• curcumin displays therapeutic potential for neurological disorders such as Alzheimer's disease.
• Several clinical trials of oral curcumin have been carried out to further investigate the therapeutic activity of this compound.
• a promising advantage of oral curcumin is that it displays minimal side effects in clinical applications as the drug.
• the practical availability of curcumin may be limited by its low bioavailability due to efficient first pass metabolism, poor gastrointestinal absorption, rapid elimination and poor aqueous solubility.
• curcumin An efficient drug delivery system is anticipated to be a breakthrough technology for the successful medical application of curcumin.
• Two main approaches are being employed to increase the bioavailability of curcumin.
• One strategy is based on the chemical modification of the curcumin molecule into water-soluble derivatives. Curcumin possesses two reactive terminal hydroxyl groups. These water-soluble curcumin derivatives might be patentable and considered as drug candidates.
• Another strategy is based on the nanoparticulate drug delivery system. Many types of blend with nanoparticles curcumin have been tested as drug delivery carriers. These nanoparticulate drug delivery systems appear to be a promising strategy for curcumin delivery.
• the process of wound healing is a series of coordinated responses to the tissue injury that results in tissue contraction, closure and restoration. This is a complex process. The longer it takes for spontaneous wound healing, the worse the outcome may be. There can be high probability of developing hypertrophic scarring and alterations in pigmentation. Under some situations, self-perpetuating inflammatory cascade may also result in increasing tissue destruction and necrosis rather than healing.
• the present invention is healing wound bed matrix containing antibiotic and biocompatible within or surfaces of the wound bed matrix in the form of fabric or in the form of bandage or in the form of fiber.
• the fabric is hydrophilic cotton which is on one side coated with zwitterionic low molecular weight chitosan and on top of that biosynthesized silver nano particles with tulsi extract are embedded on porous type mesh of zwitterionic chitosan and cotton fiber, it represents and formed wound healing matrix on woven cotton fabric.
• the said woven, water absorbent is in the form of fiber bundles.
• the nonmetallic or with silver metallic, water absorbent material is in the form of a wet and/or dry form.
• Backside of the wound bed fabric has adhesive bandage with active charcoal, glycerin and lanoline further with additional curcumin nano-particles.
• the prirnary objective of the present invention is to provide a wound healing matrix and bandage.
• Another objective of the invention is to provide a multi-purpose wound healing matrix with bandage.
• Another objective of the invention is to provide a wound healing matrix which is made up of the natural ingredients.
• the present invention provides a wound healing matrix exhibiting antibiotic, anti inflammatory, anti oxidant and biocompatible properties on the surface of wound.
• the matrix is in the form of fabric or in the form of bandage or in the form of fiber bundles.
• the fabric used is hydrophilic cotton coated with zwitterionic low molecular weight chitosan and on top of that biosynthesized silver nanoparticles are embedded.
• the bandage is coated with green synthesized silver nanoparticles with tulsi plant extract and also zwitterionic chitosan on woven or non woven fabric or fibers and/or bundles thereof.
• the matrix when being a woven material is water absorbent in nature and is in the form of fiber bundles or micro porous mesh.
• the non metallic or with silver metallic, water absorbent material is in the form of a wet and/or dry form.
• the non bleached, water absorbent material is like cotton fibers, polysaccharide material.
• the wound dressing material comprises of flexible backing material with adhesive coating and layered to one side of the base fabric which is not contact to the wound bed surface but adhering to surrounding skin of wound.
• Hydrophilic biocompatible matrix having anti microbial activity disposed on other side of the base fabric which is opposite side of the backing material layer and wound contacting surface.
• the adhesive layer, the backing layer may contain active charcoal, glycerin and landline. Further, optionally curcumin nano particles disposed on the same side as said hydrophilic bandage matrix but excluding hydrophobic bandage matrix.
• the present invention provides a multifunctional natural wound- healing matrix comprising of a wound bed made up of a hydrophilic cotton fabric coated with zwitterionic low molecular weight chitosan on one side and embedded with biosynthesized silver nano-particles on the top of that, said matrix also comprising curcumin particles, and Tulsi extracts, said matrix optionally containing neem, Aloe Vera gel, Collagen and Gelatin individually or in combination, the matrix being in the form of a fabric or bandage or fiber having an adhesive bandage on the inner side with active charcoal, glycerin and lanoline with some more additional curcumin nanoparticles on the backside of the wound bed fabric, such that all the components of the matrix are working in a synergistic way to obtain the desired healing results.
• the present invention also provides a method of preparing a multifunctional natural wound-healing matrix, wherein said method comprising the steps of:
• a primary coating comprising of 2 to 15% lanoline, 0.3 to 9 % glycerin and 0.2 to 3 % active charcoal in hexane solution;
• step (a) Applying the above primary coating of step (a) on the fabric as secondary or backing layer fabric by soaking fabric in this solution for 5 to 20 minutes and then drying at a temperature of 30 to 60 degree C for 20 to 45 minutes;
• step (d) Applying a layer of secondary coating of biologically active coating of step (d) on other fabric as base fabric obtained after step (d);
• step (h) Applying a layer of curcumin coating of step (h) on the fabric obtained after step (c) and then, medical grade adhesive disposed on specified area to obtain the final bandage;
• Figure 1 represents Matrix contains Silver nano particles enveloped with Zwitterionic chitosan.
• Figure 2 represents Multifunctional matrix showing the mesh like structure.
• Figure 3 represents Zwitter Chitosan Tulsi Silver nano-particles matrix coat on cotton gauze.
• Figure 4 represents primary coating of the gauze followed by secondary coating with Zwitter Chitosan.
• Figure 5 represents coating of Ag-Tulsi on secondary coated matrix.
• Figure 6 represents coating of nano curcumin on Ag-Tulsi coated of secondary coated matrix.
• Figure 7 represents adhesive coating to obtain final products-the wound dressing matrix.
• the present invention provides a healing wound bed matrix containing characters of antibiotic, anti-oxidant, anti-inflamatory and biocompatible within or on the surfaces of the wound.
• the matrix bed is in the form of fabric or in the form of bandage or in the form of fiber bundles or mesh.
• the base fabric is hydrophilic woven cotton which on one side is coated with zwitterionic low molecular weight chitosan and on top of that there is biosynthesized silver nano particles with tulsi extract embedded on porous type mesh of zwitterionic chitosan and cotton fiber. This forms the wound healing matrix on woven cotton fabric.
• the said woven, water absorbent is in the form of fiber bundles.
• the nonmetallic or with silver metallic, water absorbent material is in the form of a wet and/or dry form.
• Backside of the wound bed basic fabric has adhesive cotton bandage layer fabric material with active charcoal, glycerin and lanoline further with additional curcumin nano-particles.
• the invention thus provides a matrix with multifunctional for wound healing.
• the fabric used for preparing this novel matrix is either Warp and/or Weft cotton.
• the natural components which are used in various compositions for medicinal values here are: Chitosan, nano Curcumin and Tulsi.
• the said matrix comprises of Silver Nano particles with tulsi extract embedded on porous type mesh of zwitter-ionic chitosan and cotton fibers, to form wound healing matrix on woven cotton fabric.
• the base fabric is coated with composition of atleast 0.1 percent of aqueous Low molecular weight Zwitterions Chitosan.
• the silver nano-particles used in this invention are green synthesized nanoparticles of silver with tulsi plant extract in the composition of 0.1% to 100% (wt %) on woven or non woven fabric or fibres.
• the ratio of Zwitterions Chitosan and Tulsi plant extract is in different percentage. They are blend on woven, non-woven fabric or fibers thereof.
• the above three type of fabrics, bandages or fibers are useful for applying on wound healing functions, as broad range of antibacterial, anti-oxidant, antiinflammatory and biocompatible for dermal/skin tissue application.
• wound healing bed matrix which is antibiotic, anti-oxidant, anti-inflammatory and bio-compatible within or on surface of the matrix.
• Silver nano-particles with tulsi extract are embedded on porous type mesh of zwitter-ionic chitosan and cotton fibers. This represents and forms the novel and innovative wound healing matrix on woven cotton fabric of present invention.
• the hydrophilic Cotton fabric is one side coated with Zwitter-ionic low molecular weight Chitosan and on top of that biosynthesized silver nano-particles were embedded.
• the combined properties of Silver nano-particles, zwitter-ionic chitosan and tulsi extract provide a synergic effect on wound thus healing it quickly and effectively.
• the invention provides the platform to use green synthesis of silver nano-particles for development of natural wound dressing/bandage and is thus eco-friendly product.
• an adhesive fabric layer with active charcoal, glycerin and lanoline so as to restrict it from open environment and providing support to wound healing by normal activity.
• the matrix is exhibiting antibiotic, anti inflammatory, anti oxidant properties.
• the matrix is in the form of fabric or in the form of bandage or in the form of fiber.
• a hydrophilic bandage said matrix being a woven material comprising a blend of zwitterionic chitosan and green synthesized silver-coated fabric and charcoal based non allergic wound bandage.
• the said woven, water-absorbent material is in the form of fiber bundles.
• the non-metallic or with silver metallic, water-absorbent material is in the form of a wet and/or dry form.
• the non bleached, water-absorbent material is like cotton fibers, polysaccharide material.
• the said polysaccharide, plant extract tulsi material and chitosan derivative is with metallic nano-particles.
• the said hydrocolloid is a zwitterion chitosan or derivative thereof.
• the said zwitterions substance is nano-particle or low molecular weight chitosan or its derivative thereof.
• the said bio-synthesized silver nanoparticle-coated fibers are above 1 denier per filament.
• the blend comprises about 1 to about 80 percent by weight of said metallic silver- coated fibers and about 10 to about 80 percent by weight of non-metallic, water- absorbent fibers.
• the bandage blend comprises about 20 to about 70 percent by weight of said green synthesized nano-silver-coated fibers and about 20 to about 70 percent by weight of non-metallic, water-absorbent fibers.
• the metallic silver-coated fibers are numerous.
• the blend comprises about 10 to about 60 percent by weight of said biosynthesized silver-coated fibers and about 20 to about 60 percent by weight of biodegradable mesh like polysaccharide chitoson derivatives and thereof, water- absorbent, antibacterial fibers, biologically functional.
• the wound dressing is comprising a flexible backing material and a layer of a hydrophilic bandage matrix having anti-microbial activity disposed on one side of said backing material, said matrix comprising a non-woven material including a blend of nano silver-coated fibers and a non-metallic, water-absorbent material.
• the said backing layer includes an adhesive layer disposed on the same side as said hydrophilic bandage matrix but excluding said hydrophilic bandage matrix.
• the said matrix has water absorption of at least 0.05 gram per gram of matrix.
• Curcumin nanoparticles Blend of healing matrix components of wound bed matrix with Curcumin nanoparticles, with or without its constituents (chemicals), example: succinic anhydride.
• Curcumin nanoparticles are made by ultrasonic wave at least 100 rpm for 30 min at room temperature.
• a method to delivering curcumin nanoparticles was claiming that with minimum 0.1% quantity zitterionic chitosan contained.
• the present invention provides a multifunctional natural wound- healing matrix comprising of a wound bed made up of a hydrophilic cotton fabric coated with zwitterionic low molecular weight chitosan on one side and embedded with biosynthesized silver nano-particles on the top of that, said matrix also comprising curcumin particles, and Tulsi extracts, said matrix Optionally containing neem, Aloe Vera gel, Collagen and Gelatin individually or in combination, the matrix being in the form of a fabric or bandage or fiber having an adhesive bandage on the inner side with active charcoal, glycerin and lanoline with some more additional curcumin nanoparticles on the backside of the wound bed fabric, such that all the components of the matrix are working in a synergistic way to obtain the desired healing results.
• silver nanoparticles are in the size range of 56 +/- 10 nm average
• said matrix is coated with atleast 0.1% of aqueous low molecular weight zwitterions Chitosan.
• the matrix is coated with green synthesized silver nanoparticles with tulsi plant extract in the range of 0.1% to 100% (wt%).
• the two fabrics blend in as composition matrix of zwitterions chitosan, tulsi plant extract and green synthesized silver nanoparticles in different percentages, on woven, non-woven fabric or fibers and other such materials as defined herein, such that the combined properties of all the ingredients provide a synergic effect on the wound.
• the back layer of the fabric includes an adhesive layer disposed on the same side as said in hydrophilic bandage matrix, the wound dressing comprising of flexible backing material and a layer of a hydrophilic bandage matrix having antimicrobial activity disposed on one side of backing material, said matrix is comprising a nonwoven material including a blend of nano-silver coated fibers and a non-metallic, water absorbent material.
• the blend comprises of about 10% to 60% by weight of said biosynthesized silver coated fibers and about 20% to 60% by weight of green synthesized by biodegradable polymer mesh like polymers like chitosan derivatives and thereof, water absorbent, antibacterial fibers, biologically functional materials, wherein the other polymers used alternatively are derivative/composite such as from PLA, PVC, Alginate and other biocompatible polymers.
• the nonmetallic or with silver metallic, water absorbent material is in the form of a wet and/ or dry form, the matrix has water absorption of at least 0.5 gram/gram of matrix, the non bleached, water absorbent material is like cotton fibers, polysaccharide material, the said polysaccharide, plant extract tulsi material is With metallic nanoparticles, the said biosynthesized silver nano-particles-coated fibers are above one denier per filament.
• said matrix optionally comprises Collagen and Gelatin individually or both together in a range of 2% to 60% to multi-functional Zwitter Chitosan-tulsi Silver n a no-particles matrix for further improvement of biocompatibility and biological activity.
• said matrix is exhibiting antibiotic, anti inflammatory and/or anti oxidant properties.
• said fabric used for preparing matrix is non-bleached, water-absorbent material like cotton fibers, polysaccharide material.
• said woven, water-absorbent material is in the form of fiber bundles.
• said fabric with non-metallic or with silver metallic, water-absorbent material is in the form of a wet and/or dry form.
• said zwitterionic chitosan is nano-particle or a derivative thereof.
• said bio-synthesized silver nanoparticle-coated fibers are above 1 denier per filament.
• said blend comprises about 1 to about 80 percent by weight of said metallic silver-coated fibers and about 10 to about 80 percent by weight of non-metallic, water-absorbent fibers.
• the bandage blend comprises about 20 to about 70 percent by weight of said green synthesized nano-silver-coated fibers and about 20 to about 70 percent by weight of non-metallic, water-absorbent fibers.
• the blend comprises about 10 to about 60 percent by weight of said biosynthesized silver-coated fibers and about 20 to about 60 percent by weight of green synthesized biodegradable polymer mesh with polymers like chitoson and derivatives thereof, water-absorbent, antibacterial fibers and biologically functional materials.
• the wound dressing is comprising a flexible backing material and a layer of a hydrophilic bandage matrix having anti-microbial activity disposed on one side of said backing material, said matrix comprising a non- woven material including a blend of silver nano-particles coated fibers and a non- metallic polysaccharide water-absorbent material, the said backing layer including an adhesive layer disposed on the same side as said hydrophilic bandage matrix but excluding the area coated or disposed said hydrophilic bandage matrix.
• the said matrix has water absorption capacity of at least in the range of 1-5 gram per gram of matrix.
• the blend of zwitterion chitosan healing matrix with Curcumin nanoparticles is with or without its constituents (chemicals), like succinic anhydride.
• Curcumin nanoparticles are made by ultrasonic wave at least 100 rpm for 30 min at room temperature.
• the efficiency of results in antibacterial properties obtained for the matrix is 90 to 100 percent within a span of 24 to 48 hours.
• the present invention provides a method of preparing a multifunctional natural wound-healing matrix, wherein said method comprising the steps of:
• step (a) Applying the above primary coating of step (a) on the fabric as secondary or backing layer fabric by soaking fabric in this solution for 5 to 20 minutes and then drying at a temperature of 30 to 60 degree C for 20 to 45 minutes;
• step (d) Applying a layer of secondary coating of biologically active coating of step (d) on other fabric as base fabric obtained after step (d);
• step (h) Preparing curcumin nanoparticle solution in distilled water by ultrasonication to obtain next layer of coating; s) Applying a layer of curcumin coating of step (h) on the fabric obtained after step (c) and then, medical grade adhesive disposed on specified area to obtain the final bandage;
• the bandage blend comprises fabric which may alternative to cotton fibers completely or partially replaced with other biocompatible biodegradable polymers fibers or porous like sponge material as basic fabric with one or multiple characteristics like absorbent, haemostatic, homeostatic and drug delivery.
• the bandage blend comprises fabric which may be in the form of single sheath with, porous or without porous.
• Collagen and Gelatin can be added individually or in combination in a range from 2% to 60% to multifunctional Zwitterion Chitosan - tulsi Silver nano particles. This mixture can be used for semi solid liquid, solid like sponge etc. form of materials for wound healing application.
• Primary coating Materials comprising the primary coating are hexane solution mixed with 2 to 15 % lanoline, 0.3 to 9 % glycerin and 0.2 to 3 % active charcoal. These above chemicals are mixed together.
• the fabric used for preparing bandage is soaked in this solution prepared above for 10 minutes.
• the fabric is dried in hot air oven at 50 degree C for 30 minutes.
• Silver nano-particles coating An aqueous solution of sliver nano-particles with tulsi and distilled water, with silver nitrate in the range of 100 to 500 mg added to it. The fabric samples as obtained in step 2 were further coated with the solution of silver nano-particles.
• Curicumin nano-particles coating minimum 50mg/ml of aqueous solution of Curicumin nano-particles concentration were prepared. This solution was coated on the bandage fabric as obtained in step 1 to obtain the final product. Further medical grade adhesive is coated at specified area to immobilize the basic fabric and to gently attach surrounding skin of wound.
• the adhesive material layer contains with active charcoal, glycerin and lanoline with some more additional curcumin nano-particles on the layer of adhesive side.
• the wound bed of the base fabric such that all the components of the matrix are working in a synergistic way to Obtain the healthier healing results.
• the present invention is mainly for medical purpose and the applications of broad range matrix of the invention are as:
• Example 1 a. Preparing a gauze of fabric having dimension of 10X10 cm;
• step (f) Applying a layer of secondary coating of biologically active coating of step (d) on other fabric as base fabric obtained after step (c); g. Applying third coating as a layer of silver and tulsi solution (20%) on the coated fabric obtained after step (f);
• step (h) Applying a layer of 3.3 % curcumin coating of step (h) on the fabric obtained after step (g) to obtain the final wound bed matrix; then, medical grade adhesive disposed specified area (2 cm flanking from the wound bed matrix).
• the obtained matrix was subjected for in vitro bio-evaluation and was found to have antimicrobial, biocompatible and antioxidant acitivities.
• Example 2 a. Preparing a gauze of fabric having dimension of 10X10 cm;
• a primary coating comprising of 8% lanoline, 4 % glycerin and 1 % active charcoal in 100 ml of hexane; c. Applying the above primary coating on the fabric by soaking fabric in this solution for 15 minutes and then drying at a temperature of 37 degree C for 25 minutes;
• step (f) Applying a layer of secondary coating of biologically active coating of step (d) on other fabric as base fabric obtained after step (c); g. Applying third coating as a layer of silver and tulsi solution (18%) on the coated fabric obtained after step (f);
• step (h) Applying a layer of 4.8 % curcumin coating of step (h) on the fabric obtained after step (g) to obtain the final wound bed matrix; then, medical grade adhesive disposed specified area (2 cm flanking from the wound bed matrix).
• the obtained matrix was subjected for in vitro bio-evaluation and was found to have ANTIMICROBIAL, BIOCOMPATIBLE AND ANTIOXIDANT ACTIVITIES. '
• the present invention provides a zwitterions chitosan, prepared from natural chitosan by conjugating succinic anhydride molecule.
• Silver nano particles prepared by tulsi extract were mixed with zwitterion chitosan to make multifunctional effects like antibacterial, biocompatible, anti-oxidant and anti inflammatory.
• Various experiments were conducted to check the said efficacy of matrix. Antimicrobial activities were studies using following bacteria and fungi:
• the biocompatibility, anti-oxidant and anti-inflamatory property of the said matrix were evaluated using human dermal fibroblasts viability , DPPH (2,2- diphenyl-l-picrylhydrazyl) inhibition and Cox, Lox inhibition assay, respectively.
• the clear results were obtained showing termination of these bacteria within few hours of application thus indicating the efficacy of matrix components.
• the bandage was successful in destroying all the forms of bacteria and fungi within 24 hours of application.
• the matrix of present invention is not only having antibacterial properties, also anti fungal, anti-oxidant, anti- inflamatory and biocompatible properties.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Materials Engineering (AREA)
• Medicinal Chemistry (AREA)
• Vascular Medicine (AREA)
• Zoology (AREA)
• Inorganic Chemistry (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pest Control & Pesticides (AREA)
• Environmental Sciences (AREA)
• Botany (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Plant Pathology (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Agronomy & Crop Science (AREA)
• Molecular Biology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Preparation (AREA)
• Materials For Medical Uses (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=51579400

Family Applications (1)

Country Status (2)

Cited By (25)

Citations (2)

• 2014
  • 2014-01-02 WO PCT/IN2014/000002 patent/WO2014147638A1/en not_active Ceased
  • 2014-01-02 IN IN879DE2013 patent/IN2013DE00879A/en unknown

Patent Citations (2)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events